Abstract

 CADTH recommends that Dupixent be reimbursed by public drug plans for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, if certain conditions are met.
 This recommendation supersedes the CADTH Canadian Drug Expert Committee recommendation for this drug and indication on April 24, 2020. A Request for Advice was filed in 2022 by public drug programs to address an inquiry regarding the 2020 reimbursement conditions.
 Dupixent should only be covered for patients who previously tried and did not experience improvement with or are unable to use other treatments. These treatments include the highest dose of topically applied drugs combined with phototherapy (where available), and the highest dose of topically applied drugs and at least 1 of the following: methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine.
 Dupixent should only be reimbursed if prescribed by a dermatologist, allergist, clinical immunologist, or pediatrician, and if the cost of Dupixent is reduced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
